On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were available for use in the United Kingdom (U.K.).

Nuvaxovid was the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency.